ARID1A loss in cancer: Towards a mechanistic understanding

Mathur, Radhika

doi:10.1016/j.pharmthera.2018.05.001

Cited by 116 publications

(106 citation statements)

References 90 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…The SWI/SNF complexes can be further classified into sub complexes. In most of these cancers, loss of functions due to inactivating mutations in BAF250a is observed [8,9]. BAF250a (ARID1a) gene is evolutionarily conserved and shows sequence similarities with yeast SWI1 and Drosophila protein Osa, which are components of SWI/SNF complexes in these organisms.…”

mentioning

confidence: 99%

“…Association of ARID-containing proteins BAF250a (also known as ARID1a) and BAF250b (also known as ARID1b) with the SWI/SNF complex results in BAF-A and BAF-B complexes respectively, whereas the association of ARID-containing BAF200 (also known as ARID2) results in PBAF complex [1][2][3][4]. Of the three ARID-containing proteins in the mammalian SWI/SNF complexes, only BAF250a has been classified as an essential and a tumor suppressor protein [8][9][10]. BAF250a has been shown to have a role in transcriptional co-activation induced by steroid hormones [1].…”

mentioning

confidence: 99%

“…The BAF250a gene is the most frequently mutated gene of any SWI/SNF complex subunits in number of cancers that include endometriod, ovarian, gastric, bladder, melanoma, lung, breast, and pancreatic cancers [5][6][7]. In most of these cancers, loss of functions due to inactivating mutations in BAF250a is observed [8,9]. Of the three ARID-containing proteins in the mammalian SWI/SNF complexes, only BAF250a has been classified as an essential and a tumor suppressor protein [8][9][10].…”

mentioning

confidence: 99%

“…In most of these cancers, loss of functions due to inactivating mutations in BAF250a is observed [8,9]. Of the three ARID-containing proteins in the mammalian SWI/SNF complexes, only BAF250a has been classified as an essential and a tumor suppressor protein [8][9][10].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Molecular determinants of complex formation between DNA and the AT‐rich interaction domain of BAF250a

2019

View full text Add to dashboard Cite

AT‐rich interaction domain (ARID)‐containing BAF250a protein is a central DNA‐binding subunit of the SWI/SNF chromatin‐remodeling complex. ARIDs are found in several eukaryotic proteins that play roles in different aspects of cellular physiology. However, despite their biological importance, ARIDs remain relatively uncharacterized for their dynamics and DNA binding. Here, we have probed the structure and DNA‐binding properties of BAF250a ARID. We show that the core BAF250a ARID interacts with DNA sequences with low micromolar affinities. NMR chemical shift perturbation (CSP) results reveal a number of conserved residues in ARID that are involved in DNA binding. An NMR CSP‐based docking model of ARID–DNA complexes reveals that BAF250a ARID possesses necessary determinants of specific DNA binding.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Molecular determinants of complex formation between DNA and the AT‐rich interaction domain of BAF250a

2019

View full text Add to dashboard Cite

show abstract

“…ARID1A is an epigenetic‐related tumor suppressor and its main targets are regulatory elements for gene expression, known as enhancers, which are predominantly involved in developmental and differentiation programs . Important targets of ARID1A are MYC and E2F responsive promoters, which regulate the cell cycle and DNA damage checkpoint . It is interesting to note that through abolishing the interaction of ARID1A with MSH2, a protein implicated in mismatch repair, loss of ARID1A may lead to an increased sensitivity to immune checkpoint blockade …”

Section: Introductionmentioning

confidence: 99%

Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer

Dugas

Müller

Magnen

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

BACKGROUND: Mutations of AT-rich interactive domain 1 (ARID1A) have been associated with a worse outcome after intravesical treatment with bacille Calmette-Guérin in patients with non-muscle-invasive bladder cancer (NMIBC). Loss of ARID1A protein expression in urine cytology may serve as an indication of an ARID1A mutation. Therefore, the authors examined the expression of ARID1A in urine cytology and histological specimens of bladder cancer for correlation with ARID1A mutational status. METHODS: The authors constructed a tissue microarray containing samples from 164 tissue samples from 150 patients with NMIBC and 100 tissue samples from 81 patients with muscle-invasive bladder cancer. A second cohort consisted of archived cytological specimens and matched tissue sections from 62 patients with highgrade NMIBC. The authors established immunohistochemistry and immunocytochemistry (ICC) protocols, respectively, for the analysis of ARID1A protein expression in histological and cytological specimens. Confirmatory next-generation sequencing (NGS) was performed on tumor specimens using a targeted NGS panel containing all exonic regions of ARID1A. RESULTS: The prevalence of ARID1A loss of expression on the tissue microarray was 3.6% in NMIBC (6 of 164 tissue samples) and 10% in muscle-invasive bladder cancer (10 of 100 tissue samples) (P = .059). Loss of ARID1A expression in cytology was concordantly immunohistochemistry negative in 6 of 8 matched tissue specimens. NGS confirmed an ARID1A mutation on all 6 histology samples with loss of ARID1A expression. When NGS demonstrated an absence of ARID1A mutation, histology was concordantly positive (16 of 16 cases). CONCLUSIONS: The authors have suggest ARID1A ICC as a promising surrogate marker for ARID1A mutational status in patients with urothelial carcinoma. Pitfalls in ICC scoring include benign umbrella cells that often are negative for ARID1A. Further prospective studies are needed to determine the clinical relevance of ARID1A ICC in urinary cytology.

show abstract

Hepatoblastoma with neonatal necrotizing enterocolitis: Two case reports

Wang

Duan

et al. 2023

Cancer Innovation

View full text Add to dashboard Cite

We report two children with hepatoblastoma (HB) with a history of neonatal necrotizing enterocolitis (NEC). Case 1 was diagnosed with HB at 5 months of age. Liver enlargement was found during the NEC operation at 3 months of age and then was clinically diagnosed by imaging. After six chemotherapy courses, a partial hepatectomy was performed. Three months after ceasing the chemotherapy, a chest computed tomography scan suggested that distant metastasis of the tumor should be considered, and the lesion was removed. However, 9 months after the operation, alpha‐fetoprotein concentrations were increased, and abdominal imaging showed a recurrence of the tumor in situ, resulting in a hepatectomy. Case 2 was diagnosed with NEC shortly after birth and underwent an intestinal resection and anastomosis 1 month later. He was diagnosed with HB at 3 years of age. Hepatectomy was performed after five courses of chemotherapy. Chemotherapy was stopped after 10 courses, and alpha‐fetoprotein concentrations were normal. At present, both children have survived and are in a healthy condition. Physicians should be aware of the possibility of HB and a history of NEC in children. Premature birth and low birth weight are common factors leading to the pathogenesis of HB and NEC. The association between these two diseases requires further study.

show abstract

ARID1A loss in cancer: Towards a mechanistic understanding

Cited by 116 publications

References 90 publications

Molecular determinants of complex formation between DNA and the AT‐rich interaction domain of BAF250a

Molecular determinants of complex formation between DNA and the AT‐rich interaction domain of BAF250a

Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer

Hepatoblastoma with neonatal necrotizing enterocolitis: Two case reports

Contact Info

Product

Resources

About